NCT06842498View on ClinicalTrials.gov

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

FG-3246

FG-3246 will be administered per schedule specified in the arm description.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors

lead

FibroGen

INDUSTRY

NCT06842498 - A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter